While immune checkpoint blockade (ICB) agents, such as those targeting PD-L1 or CTLA4 pathways, have demonstrated clinical efficacy in some cancers, current ICB treatments do not have activity in all cancers, sometimes due to an unfavorable tumor immune microenvironment (2). Here, CTLA4 is linked to cancer.